BridgeBio Pharma Inc. (BBIO), a biopharmaceutical company focused on genetic diseases, is stepping into a season of high-stakes milestones, where science, strategy, and timing converge. Over the next few months, the company will unveil topline data from three registrational Phase 3 trials, each targeting a distinct rare disease with limited treatment options.
The first arrives on Monday, October 27, when interim results from the FORTIFY study will shed light on BBP-418's potential in Limb-girdle Muscular Dystrophy Type 2I/R9.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.